The deal is intended for the production of hyperimmune colostrum for Immuron’s products, including its Travelan treatment for travellers’ diarrhoea.
Immuron chief executive officer Joe Baini said, "As Immuron embarks on an era of increased global distribution of Travelan and other products, it is imperative to have a partner able to accommodate the anticipated significant increase in supply capacity."
Synlait Nutritionals general manager Tony McKenna said the partnership with immuron adds another value-added dairy product to the company’s suite of products.
Immuron is focused on oral therapy treatments using dairy-derived antibody products for humans.